~ Buy the TYMLOS (abaloparatide) Drug Profile, 2024 PDF Report in the Report Store ~

Drug Price Trends for TYMLOS

TYMLOS Market Analysis and Financial Projection

Market Analysis and Price Projections for Tymlos (Abaloparatide)

Introduction to Tymlos

Tymlos, developed by Radius Health, is an anabolic therapy for the treatment of osteoporosis, specifically approved for postmenopausal women at high risk of fracture and, more recently, for high-risk osteoporotic men. The drug, abaloparatide, is administered via a prefilled pen, offering a patient-friendly subcutaneous injection option[1][2][3].

Market Context: Osteoporosis Treatment

The osteoporosis market is highly competitive and is expected to undergo significant changes between 2017 and 2027. Currently, the market is dominated by generics, but the introduction of new anabolic agents and biosimilars is set to revolutionize the treatment landscape[4].

Competitive Landscape

Tymlos faces stiff competition from established drugs like Eli Lilly’s Forteo (teriparatide) and the novel sclerostin inhibitor, Evenity (romosozumab), developed by Amgen. Despite its positive results, Tymlos’s market impact is somewhat dampened by its 'me-too' status to Forteo and its once-daily subcutaneous injection regimen, which is less appealing compared to Evenity’s once-monthly dosing[2][4].

Pricing Strategy

Radius Health has priced Tymlos competitively at $19,500 per year, which is a 62% discount compared to Forteo. This pricing strategy aims to increase market share and achieve blockbuster sales status by 2025, as forecasted by GlobalData[2][3].

Market Performance and Sales

Since its launch in 2017, Tymlos has shown strong uptake in the US market. In its initial year, it generated $14 million in sales, and by 2021, it accounted for $219 million in sales, contributing significantly to Radius Health’s revenue[2][5].

Real-World Evidence and Efficacy

Recent real-world evidence presented at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases highlighted Tymlos’s efficacy in reducing hip and non-vertebral fractures compared to teriparatide. The study, which included data from over 43,000 patients, demonstrated a balanced incidence of major cardiovascular events, supporting its safety profile[1].

Expansion and Regulatory Approvals

Tymlos received FDA approval in April 2017 for postmenopausal women and expanded its approval in December 2022 to include high-risk osteoporotic men. This expansion solidifies its position as an effective therapy in the osteoporosis market[1].

Impact of Biosimilars

The arrival of biosimilars, particularly for Forteo and other market-leading branded products, is expected to significantly impact the osteoporosis market. By 2027, biosimilars are forecasted to account for a 33% share of the market, driving down prices and potentially increasing the adoption of anabolic therapies[2][4].

Market Projections

The global osteoporosis market is projected to reach $11.2 billion by 2027. Tymlos, with its competitive pricing and proven efficacy, is expected to play a significant role in this growth. GlobalData forecasts that Tymlos will reach blockbuster status by 2025, despite the competitive landscape[2].

Challenges and Opportunities

Despite the positive outlook, Tymlos faces challenges such as the limitation of its therapy to a maximum of two years per patient, poor diagnosis and treatment rates, and public perceptions of drug side effects. However, the increasing use of biosimilars and the expansion into other markets offer opportunities for growth[2][4].

Recent Corporate Developments

Radius Health was acquired by two investment firms, Gurnet Point Capital and Patient Square Capital, for $890 million in 2022. This transaction includes a contingent value right tied to Tymlos’s sales performance, highlighting the drug’s importance to the company’s future[5].

Key Takeaways

• Competitive Pricing: Tymlos is priced at $19,500 per year, a 62% discount compared to Forteo.
• Efficacy: Tymlos has shown superior efficacy in reducing fractures compared to teriparatide.
• Market Projections: The global osteoporosis market is expected to reach $11.2 billion by 2027, with Tymlos forecasted to reach blockbuster status by 2025.
• Biosimilars Impact: Biosimilars will significantly impact the market, driving down prices and increasing the adoption of anabolic therapies.
• Corporate Developments: Radius Health’s acquisition highlights the importance of Tymlos to the company’s future growth.

FAQs

Q: What is Tymlos used for?

Tymlos (abaloparatide) is used for the treatment of osteoporosis in postmenopausal women at high risk of fracture and in high-risk osteoporotic men.

Q: How is Tymlos administered?

Tymlos is administered via a prefilled pen, delivering 80μg per dose over a 30-day period through subcutaneous injection.

Q: What are the key competitors of Tymlos?

The key competitors of Tymlos include Eli Lilly’s Forteo (teriparatide) and Amgen’s Evenity (romosozumab).

Q: What is the pricing strategy of Tymlos?

Tymlos is priced at $19,500 per year, which is a 62% discount compared to Forteo.

Q: What are the market projections for Tymlos?

Tymlos is expected to reach blockbuster status by 2025, contributing to the global osteoporosis market projected to reach $11.2 billion by 2027.

Cited Sources

1. GlobalData: "Radius Pharmaceuticals' Tymlos will have to face highly competitive osteoporosis market despite positive results, says GlobalData."
2. Pharmaceutical Technology: "Global osteoporosis market to reach $11.2bn by 2027."
3. InVivo: "Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market."
4. Business Wire: "Osteoporosis: Global Drug Forecast & Market Analysis to 2027."
5. FiercePharma: "Tymlos maker Radius Health sells itself to investment firms for $890M."